Contents
Academic literature on the topic 'Protéines à domaine PDZ'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Protéines à domaine PDZ.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Protéines à domaine PDZ"
Wattiez, Anne-Sophie, and Christine Courteix. "Protéines à domaines PDZ : cibles potentielles pour le traitement de la douleur chronique." Douleurs : Evaluation - Diagnostic - Traitement 12, no. 1 (February 2011): 7–14. http://dx.doi.org/10.1016/j.douler.2010.12.003.
Full textBaulande, Sylvain, and Clotilde Langlois. "Les protéines à domaine patatine." médecine/sciences 26, no. 2 (February 2010): 177–84. http://dx.doi.org/10.1051/medsci/2010262177.
Full textAGABRIEL, J. "Avant-propos." INRAE Productions Animales 20, no. 2 (June 7, 2007): 107–8. http://dx.doi.org/10.20870/productions-animales.2007.20.2.3442.
Full textZafrani, Lara, Antoine Guillon, and Fabrice Uhel. "Techniques de détection des protéines." Médecine Intensive Réanimation 29, no. 2 (July 24, 2020): 128–34. http://dx.doi.org/10.37051/mir-00013.
Full textHeitz, Thierry. "Les multiples fonctions des protéines lipolytiques à domaine patatine." médecine/sciences 26, no. 2 (February 2010): 128–30. http://dx.doi.org/10.1051/medsci/2010262128.
Full textAlpy, Fabien, François Legueux, Laurent Bianchetti, and Catherine Tomasetto. "Les protéines à domaine START, des trafiquants intracellulaires de lipides." médecine/sciences 25, no. 2 (February 2009): 181–91. http://dx.doi.org/10.1051/medsci/2009252181.
Full textGaudreau, Coralie, Laurence Guillaumie, Emmanuelle Simon, Lydi-Anne Vézina-Im, and Olivier Boiral. "Comment promouvoir la consommation de protéines végétales : Une revue de la littérature de presse." Canadian Food Studies / La Revue canadienne des études sur l'alimentation 11, no. 1 (March 29, 2024): 66–90. http://dx.doi.org/10.15353/cfs-rcea.v11i1.613.
Full textBroc, Marianne, Mohand Hachemane, Marine Novelli, Mathieu Sourice, and Laurent Aussel. "Les bactéries, organismes de choix pour comprendre les mécanismes de réparation des protéines oxydées." médecine/sciences 36, no. 4 (April 2020): 404–7. http://dx.doi.org/10.1051/medsci/2020064.
Full textBerto, Ludovic, Anaëlle Dumazer, Fanny Malhaire, Giuseppe Cannone, Vinothkumar Kutti Ragunath, Cyril Goudet, and Guillaume Lebon. "Les avancées récentes dans le domaine de la biologie structurale des récepteurs couplés aux protéines G de la classe C : Le récepteur métabotropique du glutamate 5." Biologie Aujourd’hui 215, no. 3-4 (2021): 85–94. http://dx.doi.org/10.1051/jbio/2021013.
Full textSAUVANT, D., S. GIGER-REVERDIN, F. MESCHY, L. PUILLET, and P. SCHMIDELY. "Actualisation des recommandations alimentaires pour les chèvres laitières." INRAE Productions Animales 25, no. 3 (August 25, 2012): 259–76. http://dx.doi.org/10.20870/productions-animales.2012.25.3.3214.
Full textDissertations / Theses on the topic "Protéines à domaine PDZ"
Panel, Nicolas. "Étude computationnelle du domaine PDZ de Tiam1." Thesis, Université Paris-Saclay (ComUE), 2017. http://www.theses.fr/2017SACLX062/document.
Full textSmall protein domains often direct protein-protein interactions and regulate eukaryotic signalling pathways. PDZ domains are among the most widespread and best-studied. They specifically recognize the 4-10 C-terminal amino acids of target proteins. Tiam1 is a Rac GTP exchange factor that helps control cellmigration and proliferation and whose PDZ domain binds the proteins syndecan-1 (Sdc1), Caspr4, and Neurexin. Short peptides and peptidomimetics can potentially inhibit or modulate its action and act as bioreagents or therapeutics. We used computational protein design (CPD) and molecular dynamics (MD) free energy simulations to understand and engineer its peptide specificity. CPD uses a structural model and an energy function to explore the space of sequences and structures and identify stable and functional protein or peptide variants. We used our in-house Proteus CPD package to completely redesign the Tiam1 PDZ domain. The designed sequences were similar to natural PDZ domains, with similarity and fold recognition scores comarable to the widely-used Rosetta CPD package. Selected sequences, containing around 60 mutated positions out of 90, were tested by microsecond MD simulations and biophysical experiments. Four of five sequences tested experimentally (by our collaborators) displayed reversible unfolding around 50°C. Proteus also accurately scored the binding specificity of several protein and peptide variants. As a more refined model for specificity, we parameterized a semi-empirical free energy model of the Poisson-Boltzmann Linear Interaction Energy or PB/LIE form, which scores conformations extracted from explicit solvent MD simulations of PDZ:peptide complexes. With three adjustable parameters, the model accurately reproduced the experimental binding affinities of 41 variants, with a mean unsigned error of just 0.4 kcal/mol, andgave predictions for 10 new variants. The PB/LIE model was tested further by comparing to non-empirical, alchemical, MD free energy simulations, which have no adjustable parameters and were found to give chemical accuracy for 12 Tiam1:peptide complexes. The tools and insights obtained should help discover new tight binding peptides or peptidomimetics and have broad implications for engineering PDZ:peptide interactions
Mignon, David. "Computational protein design : un outil pour l'ingénierie des protéines et la biologie synthétique." Thesis, Université Paris-Saclay (ComUE), 2017. http://www.theses.fr/2017SACLX089/document.
Full textComputational Protein Design, or CPD is the search for the amino acid sequences compatible with a targeted protein structure. The goal is to design a new function and/or add a new behavior. CPD has been developed in our laboratory for several years, with the software Proteus which has several successes to its credit. Our approach uses a physics-based energy model, and relies on the energy difference between the folded and unfolded states of the protein. During this thesis, we enriched Proteus on several points, including the addition of a Monte Carlo exploration method with Replica Exchange or REMC. We compared extensively three stochastic methods for the exploration of sequence space: REMC, plain Monte Carlo and a heuristic designed for CPD: Multistart Steepest Descent or MSD.These comparisons concerned nine proteins from three structural families: SH2, SH3 and PDZ. Using the exploration techniques above, we were able to identify the Global Minimum EnergyConformation, or GMEC for nearly all the test cases where up to10 positions of the polypeptide chain were free to mutate (the others retaining their native types). For the tests where 20positions were free to mutate, the GMEC was identified in 2/3 of the cases. Overall, REMC and MSD give very good sequences in terms of energy, often identical or very close to the GMEC. MSDperformed best in the tests with 30 mutating positions. REMCwith eight replicas and optimized parameters often gave the best result when all positions could mutate. Moreover, compared to an exact enumeration of the low energy sequences, REMC provided a sample of sequences with a high sequence diversity.In the second part of this work, we tested our CPD model forPDZ domain design. For the folded state, we used two variants ofa GB solvent model. The first used a mean, effective protein/solvent dielectric boundary; the second one, more rigorous, used an exact boundary that flucutated over the MCtrajectory. To characterize the unfolded state, we used a set of amino acid chemical potentials or reference energies. These reference energies were determined by maximizing a likelihoodfunction so as to reproduce the amino acid frequencies in naturalPDZ domains. The sequences designed by Proteus were compared to the natural sequences. Our sequences are globally similar to the Pfam sequences, in the sense of the BLOSUM40scores, with especially high scores for the residues in the core ofthe protein. The more rigorous GB variant always gives sequences similar to moderately distant natural homologues and perfect recognition by the the Super family fold recognition tool.Our sequences were also compared to those produced by the Rosetta software. The quality, according to the same criteria as before, was very similar, but the Rosetta sequences exhibit fewer mutations than the Proteus sequences
Vogrig, Alexandre. "Synthèse et évaluation d'antalgiques originaux : les inhibiteurs de protéines à domaines PDZ." Phd thesis, Université Blaise Pascal - Clermont-Ferrand II, 2012. http://tel.archives-ouvertes.fr/tel-00803458.
Full textFournane, Sadek. "Etude des activités oncogéniques de la protéine HPV16E6 : dégradation de la protéine p53 et interaction avec les protéines à domaines PDZ." Strasbourg, 2010. http://www.theses.fr/2010STRA6203.
Full textInfection by high-risk human papillomaviruses is the main etiological factor of cervical cancer. HPV E6 oncoprotein contributes to carcinogenesis in part by its activity of p53 degradation, allowing the apoptosis inhibition. This activity needs the formation of a trimeric complex between E6, p53 and the E6AP ubiquitine ligase which induced polyubiquitination of p53 and its degradation by proteasome 26 S. Another activity of E6 is related to its ability to interact with some PDZ-containing proteins. This interaction is due to the presence of PDZ-binding motif located at the C-terminus extremity of high-risk mucosal HPV E6 protein. PDZ-containing proteins are involved in several cellular processes such the control of cell polarity, adhesion and proliferation. This thesis is focused on: (1) the study of an E6 mutant which is dominant-negatif for the degradation of p53 in HPV-positive cell line (HeLa). E6 F47R mutant has the ability to form a complex with p53 and E6AP. This trimeric complex is not able to induce p53 ubiquitination. The mutant expression in HeLa cells, induce their proliferation inhibition and p53-dependant prematured senescence. (2) identification of structural determinants of specificity interaction between HPV16 E6 and MAGI-1 PDZ1 domain : residus located upstream the PDZ-binding motif are involved in the interaction with PDZ domain. Lysine K499 and BC loop of PDZ domain are implicated in the interaction with E6 protein. By applying the same approach to others PDZ domain which are targeted by E6, it will be possible to unravel common structural rules of E6/PDZ interaction
Favre-Bonvin, Arnaud. "Altération de la fonction de la protéine à domaine PDZ TIP2/GIPC par les oncoprotéines virales Tax de HTLV-1 et E6 de HPV18." Lyon, École normale supérieure (sciences), 2005. http://www.theses.fr/2005ENSL0336.
Full textGuschinskaya, Natalia. "Caractérisation moléculaire des signaux de sécrétion des protéines sécrétées par le système de sécrétion de type II de la bactérie phytopathogène Dickeya dadantii." Thesis, Lyon 1, 2014. http://www.theses.fr/2014LYO10085/document.
Full textThe type II secretion system (T2SS) transports folded proteins from the periplasm through the outer membrane into the milieu. In many pathogenic Gram-negative bacteria, the T2SS secretes various virulence factors in host tissue and is directly involved in pathogenesis. The phytopathogen Dickeya dadantii secretes a dozen of pectinases through a T2SS named Out. The secreted proteins are lacking an obvious common signal and secretion is thought to involve multiple transient interactions of folded exoproteins with several T2SS components. Molecular nature of these interactions remains unknown. To address this question we used an in vivo sitespecific photo-crosslinking approach to capture such transient interactions within the functional T2SS of D. dadantii. In this technique, the photo-crosslinker para-benzoyl-L-phenylalanine, pBpa, is introduced in vivo in place of a residue of interest and UV-irradiation of living cells provokes the formation of complexes between the protein of interest and its partners. First, in a systematic approach, pBpa was introduced at several surface-exposed sites of the secreted protein PelI. This strategy permitted us to identify that one structural element, loop 3 of Fn3 domain in PelI, interacts both with the secretin, the outer membrane T2SS component, and with the PDZ domain of OutC, an inner membrane T2SS component. These results suggest that this loop 3 is a part of the secretion motif. The same approach permitted us to identify two other regions of PelI interacting with the T2SS: a linker situated between the two domains of PelI, which interacts with OutD, and an exposed region of the catalytic domain of PelI interacting with OutC. In another approach, pBpa was introduced into the T2SS components, OutC and OutD. These experiments suggested that the PDZ domain of OutC interacts with the secreted protein PelB. This study, in complement with other approaches, allowed us to uncover some important molecular features of the protein secretion by the T2SS
Charbonnier, Sébastian. "Structural and kinetic interaction study between the E6 oncoprotein from human papillomaviruses and PDZ domains." Université Louis Pasteur (Strasbourg) (1971-2008), 2006. https://publication-theses.unistra.fr/public/theses_doctorat/2006/CHARBONNIER_Sebastian_2006.pdf.
Full textHuman papilloma viruses infect distinct epithelial cells and cause lesions, which lead simple warts towards cancer. Two viral oncoproteins, E6 and E7, take part in a synergistical way in several cellular parthways, which can lead to immortalisation or transformation. The most cited functions are the degradation of the anti-oncogene p53 by E6 and of the protein pRb by E7. E6 is mainly implicated in the late stages of malign progression towards cancer. This correlates with its ability to degrade PDZ domain containing proteins. These proteins are located at cell-cell junctions and act as scaffolding molecules for building junction and signalisation complexes. Degradation of these proteins often induces invasive cell phenotypes. During my Ph. D. I studied the interaction between PDZ domain containing protein MAGI-1 and the C-terminal domain of E6. I produced the PDZ1 domain of MAGI-1 and the C-terminal domain of E6. Then I set up two methods for measuring protein-protein interactions by Biacore and by comparative chromatographic retention, which allowed to determine the affinity of the interaction. Finally I studied the complex by NMR. The structure calculations of the MAGI-1 PDZ1 bound to a C-terminal E6 peptide is near to completion. The detailed analysis will allow to understand the binding mechanism and the rational design of inhibitors. The interaction measurement techniques will allow to screen inhibitors directed against E6 or PDZ domains at a medium or high throughput for the aim of identifying new therapeutical molecules
Auguste, Robin. "Optimisation des voies de synthèse de nouveaux pharmacophores originaux pour le traitement des douleurs neuropathiques (OPTI-PDZ)." Electronic Thesis or Diss., Université Clermont Auvergne (2021-...), 2023. http://www.theses.fr/2023UCFA0132.
Full textAt present, neuropathic pain is arduous to relieve and its therapeutic management is largely unsatisfactory due to its resistance to conventional analgesics (paracetamol, non-steroidal anti-inflammatory drugs, opioids) and the lack of efficacy of current standard treatments (antidepressants and antiepileptics). Today, patients have a choice of two therapeutic strategies, neither of which is satisfactory: one relieves pain but is associated with significant adverse effects, while the other relies on molecules that are better tolerated but less effective. It is therefore urgent to propose therapeutic alternatives for the management of this type of pain.My thesis project proposes an innovative approach to alleviating neuropathic pain and its comorbidities, which have an impact on patient's mobility and autonomy. This approach is based on the inhibition of a major interaction between proteins involved in pain transmission, using new 'first-in-class' chemical compounds. Previous work indicates that ligands capable of interacting with proteins containing PDZ domains, such as the PSD-95 protein, to inhibit their interaction with serotonin 5-HT2A receptors, could be a promising alternative. This work has shown that the interaction between the PSD-95 protein and the 5-HT2A receptor is responsible for the serotonin resistance observed in neuropathic pain. An indole molecule capable of inhibiting this interaction and thus producing an analgesic effect was developed in the course of this work. The aim of this project is to develop a new approach to treating neuropathic pain by targeting the interaction between the 5-HT2A receptor and the PSD-95 protein using innovative aromatic nitrogen heterocycles. The aim is to develop and optimise routes of access to these molecules, to demonstrate their ability to bind to the PSD-95 protein and inhibit its interaction with the 5-HT2A receptor in vitro, and finally to exhibit an analgesic effect in vivo in an experimental model of neuropathic pain
Jané, Palli Pau. "Quantification des affinités PBM/PDZ et de leurs sites modulateurs par des approches expérimentales et informatiques à haut débit." Electronic Thesis or Diss., Strasbourg, 2020. http://www.theses.fr/2020STRAJ051.
Full textThis thesis focuses on PDZ domains, a family of globular domains that bind to conserved PDZ-Binding Motifs (called henceforth PBMs) generally situated at the extreme C-terminus of their partner proteins. Domain-motif networks are often modulated by reversible post-translational modifications (PTMs). We used synthetized PBMs to reproduce different conditions, such as a wild-type, acetylation or phosphorylation, addition of extra exosites or residue mimication of PTM in the literature. These peptides were used for interaction studies using the holdup assay, an assay originally developed in our laboratory. We evaluated the impact of diverse modifications of the PBM/PDZ interactions, which led to a global change of the PDZ-binding capability. These results provided quantitative information on the biological effects that such modifications may have in the context of full-length proteins
Blanc, Jean-Michel. "Etude moléculaire et fonctionnelle des assemblages multiproteiques impliquant les proteines de la polarité planaire Vangl2 et Scribble1." Thesis, Aix-Marseille, 2013. http://www.theses.fr/2013AIXM4131.
Full textThere are many mechanisms involved in the development of tissues that require cells or groups of cells orient and polarize. The proteins of the planar cell polarity (PCP) combine to form complexes with the membrane and create proximal-distal asymmetries. Vangl2 and Scrib1 have been identified as the first two genes involved in the PCP in mammals. In this study, I am interested in these two proteins and some of the complex in which they are involved. At first, using techniques of biochemistry, cell biology and biophysics, we showed the direct involvement of Scribble1 in traffic after endocytosis of NMDA receptors. Scrib1 interacts with NMDA receptors through its PDZ domains. Due to this binding motif between PDZ1 and PDZ2 of Scrib1, it can interact with the AP2 complex which is involved in receptor endocytosis. This study has identified a new mechanism in which Scrib1 regulates the amount of NMDA receptors on the membrane and is therefore involved in synaptic plasticity. Vangl2 is a transmembrane protein of the most upstream of the PCP pathway. We have identified a new partner named "Axin Interaction partner and Dorsalization Antagonist" (AIDA). We have shown, by yeast two-hybrid and pull down the interaction of Vangl2 with two isoforms of AIDA and collocation in COS7 and neurons. Together, these data show AIDA as a very good candidate for maintaining Vangl2 to adherens junctions and/or its membrane targeting. These studies have allowed us to improve our understanding of the mechanisms involving the planar polarity proteins